title: Age-related decrease in the opioid control of LH secretion during reproductive years in normal women.
abstract: Our previous studies showed that naloxone is unable to stimulate LH secretion in elderly men, suggesting a loss in the endogenous opioid inhibitory control of LH in senescence.
  
  
  METHODS
  In the present study, we examined whether increasing age during the reproductive period in women is associated with alterations in the LH-releasing effect of naloxone. Studies were performed in younger (age 20-28 years, n = 8) and older (age 40-48 years, n = 8) subjects with normal menstrual cycles and normal gonadal steroid levels to avoid the interference of premenopause or menopause on gonadotropin secretion. The LH response to naloxone (4 mg as an i.v. bolus plus 10 mg infused in 2 h) was tested not only in normal conditions, but also after chronic dopaminergic stimulation with bromocriptine (5 mg/day for 7 days), because this treatment has been found able to restore normal LH responses to naloxone in elderly men. All tests were performed on the 22nd day of normal menstrual cycles.
  
  
  RESULTS
  Naloxone induced a 100% increase in plasma LH levels in the younger group. In contrast, naloxone enhanced only by 50% LH secretion in the older subjects. When experiments were repeated after bromocriptine treatment, the effect of naloxone did not change in the younger subjects, whereas it was significantly higher in the older group. In the presence of bromocriptine, naloxone-induced LH increment in the older group was indistinguishable from that observed in the younger group. These data suggest that during the reproductive period, increasing age is associated with an impairment in the endogenous opioid control of LH secretion. In addition, age-related dopaminergic alterations independent of circulating gonadal steroid levels appear to underlie the defective endogenous opioid control of LH secretion in normally cycling women.
authors.affiliation: Department of Internal Medicine, School of Medicine, University of Parma, Italy.
authors.forename: V
authors.initials: V
authors.lastname: Coiro
authors.forename: R
authors.initials: R
authors.lastname: Volpi
authors.forename: D
authors.initials: D
authors.lastname: Gramellini
authors.forename: C
authors.initials: C
authors.lastname: Cigarini
authors.forename: M G
authors.initials: MG
authors.lastname: Magotti
authors.forename: G
authors.initials: G
authors.lastname: Caffarri
authors.forename: P
authors.initials: P
authors.lastname: Chiodera
mesh_terms: D000328:Adult; D000375:Aging / Q000502:physiology*; D001971:Bromocriptine / Q000494:pharmacology; D018491:Dopamine Agonists / Q000494:pharmacology; D005260:Female; D006801:Humans; D007986:Luteinizing Hormone / Q000378:metabolism*; D008597:Menstrual Cycle; D008875:Middle Aged; D009270:Naloxone / Q000494:pharmacology*; D009292:Narcotic Antagonists / Q000494:pharmacology*
chemical_list: D018491:Dopamine Agonists; D009292:Narcotic Antagonists; D009270:Naloxone; D001971:Bromocriptine; D007986:Luteinizing Hormone